GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
In this cohort study, GLP-1 RA use was associated with a lower risk of progression to cirrhosis and mortality among patients with MASLD and diabetes. The protective association was not seen in patients with existing cirrhosis, underscoring the importance of treatment earlier in the disease course.
Authors
- Hashem B. El‐Serag (ORCID: https://orcid.org/0000-0001-5964-7579)
- Yu‐Xiao Yang (ORCID: https://orcid.org/0000-0002-3690-9174)
- Roxanne Desiderio
- Steven M. Asch (ORCID: https://orcid.org/0000-0001-5838-5335)
- George T. Cholankeril (ORCID: https://orcid.org/0000-0001-5335-8426)
- Jennifer R. Kramer (ORCID: https://orcid.org/0000-0003-2953-4949)
- Basim Ali (ORCID: https://orcid.org/0000-0002-4833-307X)
- Fasiha Kanwal (ORCID: https://orcid.org/0000-0001-6715-3966)
- Liang Li (ORCID: https://orcid.org/0000-0001-5453-3839)
- Yumei Cao
- Xian Yu (ORCID: https://orcid.org/0000-0002-4043-8221)
- Mandeep Bajaj (ORCID: https://orcid.org/0000-0001-7263-5425)
- Ronald Samuel
Institutions
- Michael E. DeBakey VA Medical Center (US)
- United States Department of Veterans Affairs (US)
- The University of Texas MD Anderson Cancer Center (US)
- Baylor College of Medicine (US)
- VA Palo Alto Health Care System (US)
- Health Services Research & Development (US)
- Philadelphia VA Medical Center (US)
- Center for Innovation (US)
- University of Pennsylvania (US)
- Stanford University (US)
Publication Details
- Journal
- JAMA Internal Medicine
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1001/jamainternmed.2024.4661
- Citations
- 107
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 41.37